A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: Results of the GETUG S99 multicenter prospective study
Karim Fizazi(Université de Lille), A. Laplanche(Novartis (Switzerland)), Marie‐Stéphanie Aubelle(Centre Eugène Marquis), Pierre Kerbrat(Aarhus University Hospital), Christine Chevreau(Institut Claudius Regaud), R. Delva(Centre Eugène Marquis), Armelle Caty, F. Rolland(Institut de Cancérologie de l'Ouest), Frank Priou
Cited by 2
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k